CPTR Open Forum Development of Mechanistic/Multiscale/Systems Biology Models in Clinical Pharmacology and Translational Research: Do the Challenges Outweigh the Potential Benefits? 7:00 pm ? 9:30 pm on Tuesday, November 16, 2010 During the PSWC 2010 / AAPS Annual Meeting in New Orleans, Louisiana REGISTER ONLINE at PSWC2010.org. Multiscale models use data on sub-cellular, paracrine, and endocrine mechanisms, disease manifestations, pharmacokinetics and pharmacodynamics of therapeutics, and clinical outcomes to generate simultaneous predictions of the underlying mechanisms and outcomes of a biologic system. The goal is to provide a computational workbench that can be used to explore the ramifications of system perturbations caused by disease state(s), natural disease progression, aging, genetic abnormalities, and therapeutic intervention(s). Applied broadly, these models can extend beyond a single development project to include multiple therapeutic conditions, thereby instilling rapid, seamless information continuums across research programs. This will facilitate translational research efforts by allowing for early in silico exploration while optimizing experimental and clinical study designs. Still, there exist numerous rate-limiting steps in the evolution and utilization of these models including intellectual inertia (delineated by differing discipline nomenclatures, perspectives, and motivations to develop models), funding, training, data availability, and compelling examples.
Two brief presentations are planned to provide examples of multiscale model development and implementation. Panelists will offer academic, regulatory and industry perspectives to add to an open discussion of the benefits and challenges we face in moving multiscale modeling forward. Join us at the 2010 CPTR Open Forum. It promises to be a lively evening of food, drink, and exchange of scientific ideas. Session Chair Matthew Riggs, Ph.D. Metrum Research Group LLC Final Agenda Opening Remarks Matthew Riggs, Ph.D. Benefits and Challenges: Model-Driven Drug Development from Target Identification Through Clinical Development Matthew Onsum, Ph.D. Merrimack Pharmaceuticals Open Panel Discussion
